81,23 €
Deine Einschätzung
Edwards Lifesciences Corp. Aktie
Was spricht für und gegen Edwards Lifesciences Corp. in den nächsten Jahren?
Pro
Kontra
Rendite von Edwards Lifesciences Corp. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Edwards Lifesciences Corp. | -0,87 % | -4,66 % | -4,93 % | 5,63 % | 17,11 % | 9,36 % | 366,36 % |
QuidelOrtho Corp. | -0,55 % | -10,45 % | -20,16 % | -56,38 % | -46,92 % | -66,51 % | - |
Boston Scientific | -0,78 % | -1,55 % | 2,65 % | 34,96 % | 23,44 % | 86,00 % | 103,46 % |
Illumina Inc. | -0,34 % | -10,00 % | -8,41 % | -47,32 % | -14,69 % | -67,07 % | -61,43 % |
Kommentare
News
Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024.
Bernard Zovighian, chief executive officer, and
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023.
Highlights and Outlook
-
Q4 sales grew 14 percent to $1.53 billion; constant currency1